Close
Close

Anti-EGFR (423103) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-WFY6560)

Online Inquiry  Datasheet

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-EGFR chimeric antigen receptor (CAR) is constructed for the engineering of T cells to target Human EGFR. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-EGFR antibody linked to 4-1BB(CD137), OX40 and CD3ζ signaling domains. And the vector product was designed for the treatment of multiple myeloma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • EGFR
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Plasma membrane
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells and binds to a high-affinity ligand (4-1BB) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMS, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound.CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • 423103
  • Host
  • Rat
  • Target Species
  • Human
  • Gene Name
  • Epidermal Growth Factor Receptor
  • Synonyms
  • EGFR;EGFR; Epidermal Growth Factor Receptor; Epidermal Growth Factor Receptor; Receptor Tyrosine-Protein Kinase ErbB-1; Erb-B2 Receptor Tyrosine Kinase 1; Proto-Oncogene C-ErbB-1; EC 2.7.10.1; ERBB1; ERBB; HER1; Epidermal Growth Factor Receptor (Avian Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog); Erythroblastic Leukemia Viral (V-Erb-B) Oncogene Homolog (Avian);

Customize Your CAR Products

Customize Your CAR Products
Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
CAR scFv data FCM

Fig.1 Treatment with panitumumab resulted in the saturation of EGFR on A431 epidermoid carcinoma cells in vitro and in vivo in xenograft tumors as determined by flow cytometry.

CAR Construction : Latest CAR Construction

Fig.1 Treatment with panitumumab resulted in the saturation of EGFR on A431 epidermoid carcinoma cells in vitro and in vivo in xenograft tumors as determined by flow cytometry.

A431 cells were incubated in vitro with increasing concentrations of unlabeled panitumumab and phycoerythrin (PE)-labeled panitumumab to determine lowest concentration required to achieve cell-surface binding saturation.

Freeman, D. J., McDorman, K., Ogbagabriel, S., Kozlosky, C., Yang, B. B., Doshi, S., ... & Radinsky, R. (2012). Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Molecular Cancer, 11(1), 1-11.
CAR scFv data FuncS

Fig.2 Mice with established A431 tumors received PBS (purple line), human IgG2 500 μg (blue line), panitumumab 5 μg (orange line), 20 μg (brown line), 200 μg (red line) or 500 μg (green line) for 52 days.

CAR Construction : Latest CAR Construction

Fig.2 Mice with established A431 tumors received PBS (purple line), human IgG2 500 μg (blue line), panitumumab 5 μg (orange line), 20 μg (brown line), 200 μg (red line) or 500 μg (green line) for 52 days.

Observed and model-fitted tumor growth curves in an A431 carcinoma xenograft model.

Freeman, D. J., McDorman, K., Ogbagabriel, S., Kozlosky, C., Yang, B. B., Doshi, S., ... & Radinsky, R. (2012). Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer. Molecular Cancer, 11(1), 1-11.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-EGFR (423103) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-WFY6560). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

CAR Vector Products

CAR-MA Cell Products

CAR Viral Particles

CAR mRNA

CAR Cell Products

CAR-MA Vector Products

CAR Animal Cells

Online Inquiry
Products
Global Services
Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.
Copyright © 2024 Creative Biolabs. All Rights Reserved
Cart
    Go to checkout